US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Pasithea Therapeutics Corporation (KTTA)
Pasithea Therapeutics Corporation (KTTA) ニュース

KTTA

Pasithea Therapeutics (KTTA)

Pasithea Therapeutics Corporation

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:KTTA

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/13	19 : 59	GlobeNewswire Inc.	Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/05/28	19 : 59	GlobeNewswire Inc.	Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/04/29	20 : 59	GlobeNewswire Inc.	Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/04/24	20 : 59	GlobeNewswire Inc.	Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/02/13	21 : 59	GlobeNewswire Inc.	Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/01/19	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/01/08	21 : 59	GlobeNewswire Inc.	Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/01/03	06 : 47	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/01/02	22 : 35	GlobeNewswire Inc.	Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/12/29	07 : 00	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/12/29	07 : 00	GlobeNewswire Inc.	Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/12/29	01 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/12/20	07 : 26	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/12/20	07 : 21	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/12/20	07 : 19	GlobeNewswire Inc.	Pasithea Therapeutics Announces Results from 2023 Annual Meeting	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/12/11	22 : 01	GlobeNewswire Inc.	Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/11/30	07 : 00	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/11/30	06 : 27	GlobeNewswire Inc.	Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/11/29	21 : 59	GlobeNewswire Inc.	Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/11/14	06 : 45	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/11/09	21 : 59	GlobeNewswire Inc.	Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/10/27	06 : 01	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:KTTA	Pasithea Therapeutics Corporation

Showing the most relevant articles for your search:NASDAQ:KTTA

1 2 3 4 5 6 7 次へ >>

Deutsche Telekom (QX)

Health Care Select Sector

BNP Paribas (QX)

US Dollar vs Yen

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約